/**
 * Quick Review content for Topic 16 - Fibrinolysis. Inhibition of clotting in vitro and in vivo
 * Auto-generated by Quick Review Generator
 */
const topic16QuickReview = {
  topicId: 'topic-16',
  topicNumber: 16,
  learningObjectives: {
    'lo-1': {
      title: '>>Expound the activation and regulation of the plasmin system.<<',
      isCritical: true,
      blocks: [
        { type: 'header', text: 'Plasmin System: Fibrinolysis Mechanism', critical: true },
        { type: 'paragraph', text: 'Plasminogen (inactive precursor from liver) converts to plasmin (active enzyme) to break down fibrin clots.', critical: true },
        { type: 'list', intro: 'Activation pathways:', items: [
          'tPA (tissue plasminogen activator) - primary: released from endothelial cells, binds fibrin in clot',
          'uPA (urokinase) - tissue remodeling and cell migration',
          'Factor XIIa → kallikrein pathway',
          'Streptokinase - bacterial enzyme used clinically'
        ], critical: true },
        { type: 'paragraph', text: 'Plasmin degrades fibrin, fibrinogen, Factor V, and Factor VIII, producing fibrin degradation products (FDPs) including D-dimer (fibrinolysis marker).', critical: true },
        { type: 'comparison',
          left: {
            title: 'Activation Inhibitors',
            items: [
              'PAI-1 (plasminogen activator inhibitor-1)',
              'From endothelial cells',
              'Blocks tPA and uPA',
              'Prevents plasminogen activation'
            ]
          },
          right: {
            title: 'Plasmin Inhibitors',
            items: [
              'α2-antiplasmin - main inhibitor',
              'Binds free plasmin in blood',
              'TAFI (thrombin-activatable fibrinolysis inhibitor)',
              'Modifies fibrin → resistant to plasmin'
            ]
          }
        },
        { type: 'keypoint', text: 'Balance: Activation (tPA, uPA) vs Regulation (PAI-1, α2-antiplasmin, TAFI) maintains controlled fibrinolysis within clots only.', critical: true }
      ]
    },
    'lo-2': {
      title: '>>Describe the following systems and their regulation: thrombomodulin/protein C/protein S; heparin/antithrombin.<<',
      isCritical: true,
      blocks: [
        { type: 'header', text: 'Natural Anticoagulant Systems', critical: true },
        { type: 'paragraph', text: 'Two major systems prevent excessive clotting in vivo:', critical: true },
        { type: 'steps', intro: 'System 1: Thrombomodulin/Protein C/Protein S', items: [
          'Thrombomodulin (transmembrane protein on endothelium) binds thrombin',
          'Thrombin changes from procoagulant → anticoagulant',
          'Thrombin-thrombomodulin complex activates protein C → APC (activated protein C)',
          'Protein S (vitamin K-dependent cofactor) enhances APC activity (only free form active)',
          'APC + protein S inactivate Factor Va and Factor VIIIa',
          'Reduces prothrombinase and tenase complexes → limits thrombin generation'
        ], critical: true },
        { type: 'keypoint', text: 'Regulation: Requires vitamin K for protein C/S synthesis, adequate thrombin levels, and thrombomodulin expression on endothelium.', critical: true },
        { type: 'steps', intro: 'System 2: Heparin/Antithrombin', items: [
          'Antithrombin (AT/ATIII) - serine protease inhibitor from liver',
          'Inhibits: Thrombin (IIa), Factor Xa (primary targets), also IXa, XIa, XIIa',
          'Heparin (glycosaminoglycan from mast cells/basophils) binds AT',
          'Conformational change enhances AT activity up to 1000-fold',
          'Heparin-AT complex rapidly inactivates thrombin and Factor Xa',
          'Prevents fibrinogen → fibrin conversion'
        ], critical: true },
        { type: 'comparison',
          left: {
            title: 'Protein C/S System',
            items: [
              'Vitamin K-dependent',
              'Inactivates Va, VIIIa',
              'Requires thrombomodulin',
              'Natural regulation'
            ]
          },
          right: {
            title: 'Heparin/AT System',
            items: [
              'Immediate when given exogenously',
              'Inhibits IIa, Xa (mainly)',
              'Enhances natural AT',
              'Used therapeutically'
            ]
          }
        }
      ]
    },
    'lo-3': {
      title: '>>Enlist substances that can be used to inhibit blood coagulation in vitro (EDTA, citrate) and define their mechanism of action.<<',
      isCritical: true,
      blocks: [
        { type: 'header', text: 'In Vitro Anticoagulants', critical: true },
        { type: 'paragraph', text: 'Calcium (Ca²⁺) is essential for multiple coagulation steps. Removing or binding calcium prevents clotting in lab samples.', critical: true },
        { type: 'table',
          headers: ['Substance', 'Mechanism', 'Application'],
          rows: [
            ['EDTA', 'Chelates Ca²⁺, making it unavailable', 'CBC (complete blood count) tubes'],
            ['Citrate', 'Binds Ca²⁺ forming soluble complexes', 'PT/aPTT tests, blood banks (reversible)'],
            ['Oxalates', 'Precipitates Ca²⁺ as insoluble oxalate', 'Specific laboratory tubes'],
            ['Heparin', 'Enhances antithrombin activity', 'Some lab samples requiring liquid blood']
          ]
        },
        { type: 'keypoint', text: 'Calcium is required for activation of Factors II (prothrombin), VII, IX, and X. Removing Ca²⁺ blocks the coagulation cascade.', critical: true },
        { type: 'clinical', text: 'Citrate is reversible (add Ca²⁺ back for testing), making it ideal for coagulation tests like PT and aPTT.' }
      ]
    },
    'lo-4': {
      title: '>>Enlist substances and drugs that can be used in vivo to inhibit thrombocyte activation and blood coagulation or to facilitate fibrinolysis<< (inhibitors of cyclooxygenase, heparin, vitamin K antagonists, plasminogen activators).',
      isCritical: true,
      blocks: [
        { type: 'header', text: 'In Vivo Anticoagulants & Fibrinolytics', critical: true },
        { type: 'list', intro: 'Four major drug classes:', items: [
          'COX inhibitors (antiplatelet)',
          'Heparin (anticoagulant - immediate)',
          'Vitamin K antagonists (anticoagulant - long-term)',
          'Plasminogen activators (fibrinolytic)'
        ], critical: true },
        { type: 'steps', intro: '1. COX Inhibitors (Antiplatelet)', items: [
          'COX enzyme converts arachidonic acid → prostaglandins + thromboxane A2 (TXA2)',
          'TXA2 promotes vasoconstriction and platelet aggregation',
          'Aspirin irreversibly acetylates COX',
          'Blocks TXA2 formation → reduces platelet aggregation'
        ] },
        { type: 'steps', intro: '2. Heparin (Anticoagulant - Immediate)', items: [
          'Binds antithrombin III (AT)',
          'Enhances AT inhibition of thrombin (IIa) and Factor Xa',
          'Immediate effect',
          'Used for acute thromboembolic prevention/treatment'
        ], critical: true },
        { type: 'steps', intro: '3. Vitamin K Antagonists (Anticoagulant - Long-term)', items: [
          'Examples: Warfarin, acenocoumarol',
          'Inhibit vitamin K epoxide reductase enzyme',
          'Reduces synthesis of vitamin K-dependent factors (II, VII, IX, X) and proteins C, S',
          'Used for atrial fibrillation, venous thromboembolism prevention'
        ], critical: true },
        { type: 'steps', intro: '4. Plasminogen Activators (Fibrinolytic)', items: [
          'Examples: tPA, urokinase, alteplase, streptokinase',
          'Convert plasminogen → plasmin',
          'Plasmin degrades fibrin clots',
          'Used acutely in MI, ischemic stroke, pulmonary embolism'
        ], critical: true },
        { type: 'comparison',
          left: {
            title: 'Antiplatelet/Anticoagulant',
            items: [
              'Aspirin - prevents clot formation',
              'Heparin - immediate effect',
              'Warfarin - long-term prevention',
              'Used prophylactically'
            ]
          },
          right: {
            title: 'Fibrinolytic',
            items: [
              'tPA/alteplase/streptokinase',
              'Breaks down existing clots',
              'Acute use only',
              'Emergency treatment (MI, stroke, PE)'
            ]
          }
        },
        { type: 'clinical', text: 'Aspirin for prevention, heparin for immediate anticoagulation, warfarin for long-term, tPA/alteplase for acute clot dissolution.' }
      ]
    }
  }
};

export default topic16QuickReview;
